Sunitinib, a broad-spectrum small-molecule inhibitor of receptor tyrosine kinases (RTKs), is currently the standard treatment for first-line treatment of advanced clear cell renal cell carcinoma (ccRCC). Here, NTRK1 is linked to nonpapillary renal cell carcinoma.